RIGI and cancer: Lastly, the differences we identified between 5′-pppA and 5′-pppG RNAs should be considered when designing RIG-I agonists, which can be used to trigger broad antiviral responses (Supplementary Figure S3) (71,72) or promote IFN-I-dependent apoptosis, potentially serving as anti-cancer agents (73).